Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab

Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab

Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not bee...

Full description

Bibliographic Details
Main Authors: Atsuto Mouri, Satoshi Watanabe, Takaaki Tokito, Yoshiaki Nagai, Yu Saida, Hisao Imai, Ou Yamaguchi, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Series:Cancers
Subjects:
nivolumab
ipilimumab
durvalumab
CCRT
non-small-cell lung cancer
Online Access:https://www.mdpi.com/2072-6694/16/7/1409

Internet

https://www.mdpi.com/2072-6694/16/7/1409

Similar Items